Hypertension in special population, those with type II diabetes, obesity and kidney disease
5 June 14:30 to 15:30 PM UAE Time
by Dr. Nizar AtallahClick Here To Register
CME being applied for.
Webinar Objective and Description:
For the meeting, the objective will be to provide updates on hypertension urgency and emergency and updates on the latest ESH 2018 guidelines, studies on BP targets, and to highlight the studies and evidence related to ACE inhibitor Perindopril/ Indapamide/ Amlodipine single pill combination in hypertension management in hypertensive patients with type II diabetes, obesity and kidney disease.
a) Highlight which patients would benefit from RAASi/Diuretic and CCB combinations.
b) Highlight the place of RAASi/ Diuretic and RAASi combinations in the guidelines.
c) Highlight importance of single-pill combinations in the management of CV diseases
Dr. Nizar Atallah is Clinical Associate Professor of Medicine, in University of Kentucky Medical School, Lexington, Kentucky, USA and Consultant in Nephrology and renal transplantation in Cleveland Clinic, Abu Dhabi. Dr. Nizar is an expert in hypertension in the UAE. His main areas of interest include managing patients with resistant hypertension and improving outcomes and quality of life of patients with combined heart failure and kidney disease. He is Clinical professor of medicine at the Cleveland Clinic Lerner’s College of Medicine in Cleveland, Ohio (USA). During his career, he published several abstracts and papers in peer-reviewed journals on immunosuppressive regimens in kidney transplantation, secondary hypertension, cardio-renal syndrome and prevention of complications of chronic kidney disease.
If you live in: UAE, Qatar, Oman, Bahrain, Kuwait: Sign up to stay in touch with Servier GCC updates through digital Media
If you live in: Saudi Arabia: Sign up to stay in touch with Servier GCC updates through digital Media
To view the Summary of Product Characteristics for your country click on the following link: https://iservier.com/gccdocs/
For Medical Information Queries email [email protected]
For pharmacovigilance (PV) cases please contact [email protected]Click Here To Register